Kornimate/medical-research-clean huggingface dataset:
phantom motor execution via mpr, vr/ar, and sg, as a treatment of plp

Conditions: Phantom Limb Pain

Summary: this international, multi-center, double-blind, randomized, controlled clinical trial aims to evaluate the efficacy of phantom motor execution (pme) and phantom motor imagery (pmi) as treatments of phantom limb pain (plp). in pme, myoelectric pattern recognition (mpr) is used to predict motor volition and then use the decoded movements to control virtual and augmented reality environments (vr/ar), along with serious gaming (sg). the same device and vr/ar environments are used in pmi with the difference that subjects will imagine rather than execute phantom movements. electromyography is used to monitor for no muscular activity in pmi.

sixty-six subjects with upper or lower limb amputations are planned to take part in this study. subjects will be assigned randomly to pme and pmi treatments (2:1 proportion). after treatment completion (15 sessions of 2 hours each) and follow-up period of six months, patients that received pmi will be given the choice to receive pme. the design is double blinded as the patient will be informed that the treatment received, regardless of which, has been shown effective in previous studies. the person conducting the pain evaluations will be blinded to which treatment each patient receives, and will not take part on providing treatment (evaluator and therapist are different persons).

Eligibility criteria:
* subject must be older than 18 years. * if the subjects are under pharmacological treatments, there must be no variations on the medicament dosages for at least one month (steady consumption). * the last session of previous treatments must be at least 3 months old. * any pain reduction potentially attributed to previous phantom limb pain treatments must be at least 3 months old. * subjects must have control over at least a portion of biceps and triceps muscles for upper limb amputations, and quadriceps and hamstrings for the lower limb amputations. * the subject has signed a written informed consent. * the subject must be in a stable prosthetic situation (i.e. satisfied with the fitting of the prosthesis) or being a non user. * at least six months should be passed since the amputation: acute phantom limb pain cases should not be included in the study. * the patient subject should not have a significant cognitive impairment that prevents the patient from following instructions. * subjects with abundant soft tissue on their stump will not be automatically excluded, however, an evaluation in the system is required to analyze if sufficient electromyography signals can be recorded. * subjects for whom skin contact or muscle contraction are painful (nrs \> 2) are not eligible for the study. * the subject should not have any condition associated with risk of poor protocol compliance. * the subject should not have any other condition or symptoms preventing the patient from entering the study, according to the investigator´s judgement.
the long-term effects of an intensive lifestyle intervention for type 2 diabetes on medicare outcomes

Conditions: Type 2 Diabetes Mellitus

Summary: this study investigates whether an intensive lifestyle intervention for type 2 diabetes had long-term effects on medicare enrollment, health care use, and health care spending.

the look ahead study tested whether participants with type 2 diabetes assigned to an intensive lifestyle intervention (ili) for weight loss exhibited reductions in cardiovascular morbidity and mortality, relative to a control group receiving usual care and diabetes support and education. during the 12-year intervention period, the ili led to persistent reductions in weight, waist circumference, and hemoglobin a1c and improvements in physical fitness. in addition, the ili led to reductions in hospitalizations, hospital days, and prescription drug spending during the intervention period (through 2012). however, the longer-term effects (2012 and later) on health care use and spending remain unknown. in an ongoing ancillary study, the researchers are investigating the effects of the ili on economic outcomes, during and after the study. as a part of this study, the study team is linking consenting look ahead participants to medicare databases. the researchers will investigate the long-term effects of ili on health care use and health care spending. by 2012 nearly all look ahead participants were eligible for medicare due to age (over 65). to the extent that look ahead participants developed severe disabilities, the participants may have gained medicare eligibility earlier through enrollment in social security disability insurance (ssdi). thus, the researchers will also test for differences in the medicare enrollment channel between ili and control group participants, specifically whether the groups enrolled through ssdi at different rates.

Eligibility criteria:
inclusion criteria: * look ahead participation: met age requirements and other criteria at time of study enrollment (as noted in look ahead research group (2013)) * consented to administrative data linkages * provided individual identifiers that could be linked with medicare databases * were successfully linked to medicare data exclusion criteria: -
relationship between different administration regimens of ceftazidime/avibactam and clinical outcomes

Conditions: Anti-Infective Agent

Summary: ceftazidime/avibactam (caz/avi) is a new β-lactam drug, which has good antibacterial effect against carbapenem resistant enterobacter. however, previous studies found that caz/avi had a low pk/pd compliance rate after the recommended dose of the drug instructions.therefore, this study was intended to explore the clinical efficacy of different administration schedules of caz/avi for patients with severe infection, and further analyze the correlation between caz/avi pk/pd parameters and clinical efficacy and adverse reactions.

1. main purpose the main objective of this study was to verify that the clinical efficacy of treatment group (load dose of 2.5g, then continuous infusion of 2.5gq8h, the dose can be adjusted according to renal function) with severe infection was superior to that of the control group (standard dose and administration regimen of ceftazidime/avibactam, i.e. 2.5gq8h, 2h infusion).dose can be adjusted according to renal function). 2. secondary purpose (1) to investigate the relationship between different administration regimens and bacterial clearance and 28-d mortality (2) to explore the correlation between different dosing regimens and pk/pd compliance rate (3) to explore the correlation between different administration regimens and adverse drug reactions

Eligibility criteria:
inclusion criteria: multiple-resistant negative bacteria sensitive to ceftazidime/avibactam received intravenous infusion of ceftazidime/avibactam exclusion criteria: allergic to ceftazidime/avibactam blood sample not be collected pregnant or lactating

Keywords: anti-infective agent
hexoskin medical system - ecg performance testing

Conditions: Cardiac Rhythm Disturbance

Summary: the goal of this observational study is to validate the efficacy of the hexoskin medical system (hms) for its intended use (i.e., manual assessment of cardiac rhythm disturbances) in non-critical adult participants who are suspected of having an arrhythmia or have evidence of arrhythmia requiring monitoring via 24-hour holter monitor.

the main questions it aims to answer are: 1. whether the hms ecg recordings can be used to accurately detect cardiac beats when compared with the holter monitor 2. whether there are good agreements between the hms and holter monitor in ecg characteristics 3. whether the hms ecg recordings can be used to accurately classify cardiac rhythm/rhythm disturbance when compared with the holter monitor 4. what is the accuracy of using hms ecg recordings to detect cardiac beats 5. what is the accuracy of using hms ecg recordings to identify cardiac rhythm/rhythm disturbance participants will wear the hms and the holter monitor at the same time to record ecg signals. researchers will evaluate the ecg recordings acquired from both devices and assess the above questions.

Eligibility criteria:
inclusion criteria: * provision of signed and dated informed consent form. * stated willingness to comply with all study procedures and availability for the duration of the study. * male or female, aged 21 years or older. * participants must be suspected of having an arrhythmia or have evidence of arrhythmia requiring monitoring via 24-hour holter monitor. exclusion criteria: * body circumference that is not covered by the hms shirt sizing chart * presence of pacemaker or implantable cardioverter-defibrillator (icd) devices * known allergic reactions to silver or polyamide/polyester/elastane * known allergic reactions to ecg gel electrodes * documented medical condition or illness requiring intensive medical treatment or care

Keywords: hexoskin medical system (hms) cardiac rhythm disturbance
investigation of the atherogenic effects of uric acid-modified in endothelial dysfunction and the the preventional mechanism by anthocyanidines

Conditions: Cardiovascular Disease

Summary: the purpose of this study is to confirm the protective effect and mechanism of anthocyanins on hyperuricemia patients with cardiovascular disease.

hyperuricemia patients who have the ability to complete the intervention study in the early stage of study were selected as the research subjects. a randomized controlled double blind control method was used to study the effect of one year of anthocyanins intervention. serum ua levels, oxidative stress, ages, and endothelial function are detecting in patients with hyperuricemia who were treated with anthocyanins and placebo. providing scientific basis of anthocyanins for the treatment with hyperuricemia and delaying atherosclerosis.

Eligibility criteria:
inclusion criteria: * serum uric acid \>420μmol/l (7mg/dl) in male, \>360μmol/l (6mg/dl) in female identified as hyperuricemia patients. exclusion criteria: * age more than 60 years and less than 30 years old; * acute infection, tumor, recent surgery, need for hemodialysis and autoimmune diseases.

Keywords: hyperuricemia endothelial function anthocyanidins
anti-hypertensive medication dosing regimen in effective blood pressure control

Conditions: Hypertension

Summary: a randomised crossover trial of anti-hypertensive medication dosing regimen in effective blood pressure control. to investigate whether there is a difference in 24 hour blood pressure (bp) control when antihypertensive medications are taken in the morning compared with the evening.

the identification of any significant difference could lead to more effective therapeutic management of arterial hypertension, which in turn would result in a reduced cardiovascular burden, lower costs and a better quality of life for hypertensive patients.

Eligibility criteria:
inclusion criteria: * caucasian patients aged 18-80 years; * history of any grade of hypertension for at least 1 year, including at least 3 months of constant antihypertensive medication (consisting of ≥ 1 antihypertensive drugs, each administered in one dose daily), with reasonably controlled bp (≤150/90 mmhg and ≥ 115/75 mmhg on usual medication) based on previous clinic records, in the last 3 months. exclusion criteria: * bp levels \> 150/90 mmhg or \< 115/75 mmhg in the last 3 months. * postural hypotension, defined as symptoms resulting from a \> 20 mm hg drop of systolic bp or a \> 10 mm hg drop of diastolic bp or both between 1 and 3 min after standing from the sitting position. * known extreme dippers at baseline (fall of mean night time sbp \> 20% of mean day time sbp) * individuals with jobs which require night-time shift work. * pregnant women or those planning to become pregnant.

Keywords: hypertension
diclofenac suppository to control pain during flexible cystoscopy

Conditions: Pain; Hematuria; Lower Urinary Tract Symptoms

Summary: flexible cystoscopy has diagnostic as well as therapeutic role in many patients presenting in urology clinic with lower urinary tract symptoms (frequency, nocturia etc) and hematuria (blood in urine). pain associated with cystoscopy varies from patient to patient, majority requires local anesthesia or lubricant solution only. during flexible cystoscopy, lubrication, use of topical anesthesia and duration of cystoscopy are recognized as important factors contributing in severity of pain of which use of intraurethral gel left to individual preference. various studies are available reporting the pain perception with use of various intraurethral gels. even the highest level of evidence is unable to resolve the query. with this study the investigators hypothesize that pain perception (recorded in form of pain score) during flexible cystoscopy can be reduced with use of per operative diclofenac(non steroidal anti inflammatory drug)suppository in comparison to plain gel alone. with better control of pain the investigators aim to increase patient comfort and compliance which will increase the patient satisfaction rate and early return to work.


Eligibility criteria:
inclusion criteria: * all male patients aged 18 and above * visiting for evaluation of haematuria or * lower urinary tract symptoms (which include poor steam of urine,intermittency, hesitancy, incomplete voiding of urine, increase urgency, increase frequency, nocturia and urge incontinence) * for removal of double j ureteral stent will be included in the study. exclusion criteria: * patients with clinical evidence of urethral stricture and/or prostatitis, * patients in which biopsy will be taken, * those having psychiatric illness, * asthmatics * kidney, liver disease * those allergic to nsaids (non-steroidal anti-inflammatory drugs) * those who refuse to participate, * having history of chronic analgesia use or * having language barrier will be excluded.

Keywords: flexible cystoscopy pain control diclofenac non steroidal anti inflammatory drug
safety, tolerability and pk of shr1314 in axspa

Conditions: Axial Spondyloarthritis

Summary: the main purpose of this study is to evaluate the safety, tolerability and pharmacokinetics (pk) of shr1314 with axial spondyloarthritis.

this was a phase i, multicenter, double-blind, randomized, placebo-controlled study. the study originally planned to enroll 5 cohorts of 8 subjects each (n=40).

Eligibility criteria:
inclusion criteria: 1. diagnosis of axial spondyloarthritis (axspa) and fulfilling the 2009 asas classification criteria. 2. have a history of back pain ≥3 months with age at onset \<45 years. 3. have active axspa defined as basdai ≥4 at screening and baseline. 4. have objective signs of inflammation by presence of elevated esr and/or presence of elevated crp. 5. in the past had an inadequate response to at least 1 or 2 non-steroidal anti-inflammatory drugs (nsaids) for duration of 4 weeks or cannot tolerate nsaids. 6. if taking nsaids be on stable dose for at least 2 weeks prior to randomization. exclusion criteria: 1. history of ongoing, chronic or recurrent infectious disease or evidence of tuberculosis infection. 2. previous exposure to other biologic drug directly targeting interleukin (il)-17 or interleukin (il)-17 receptor. 3. total ankylosis of the spine. 4. have recently received biologics, tumor necrosis factor inhibitors or other immunomodulatory agents within 12 weeks. 5. have either a current diagnosis or a recent history of malignant disease. 6. are pregnant or breastfeeding.

Keywords: shr1314
resistant bacteria in children in france

Conditions: Infection Due to Resistant Bacteria; Multi-antibiotic Resistance; Antibiotic Prescription; Risk Factors; Healing; Complications; Intensive Care Unit; Hospital Discharge; Outcome, Fatal

Summary: this study is observational, multicenter and prospective study for surveillance of the use of new antibiotics in pediatrics for treated pediatrics infections due to multi-resistant bacteria

the main of this study is to evaluate the relevance of prescribing "new antibiotics" according to the antibiogram of the isolated bacteria or in the absence of bacteriological documentation as this is a surveillance study, the clinical and biological characteristics of the children included will be described.

Eligibility criteria:
inclusion criteria: * children under 18 years of age * hospitalized in france in a hospital center working with the activ/gpip network * treated with one or more of the following antibiotics: * colimycin (colistimethate sodium) * cefiderocol * aztreonam in combination * ceftolozane-tazobactam * ceftazidime-avibactam * meropenem/vaborbactam * imipenem/relebactam * tigecycline * daptomycin * ceftaroline fosamil * tedizolid phosphate * fidaxomicin * ceftobiprole * dalbavancin in association with a documented infection performed by: * blood culture * normally sterile site * cerebrospinal fluid * pleural fluid * pleura * peritoneum * joint fluid * other * urine sampling if the bacteria was considered responsible for the infection (associated with a leukocyturia ≥10,0000) * respiratory specimens if the bacteria was considered responsible for the infection * sampling on material such as:intubation probe, orthopedic, urological, central nervous system (cns),.... * related to colonization with multidrug-resistant bacteria without documentation. exclusion criteria: * refusal of participation by the patient or his/her parent * medical history of mucoviscidosis
cognitive behavioral therapy for depression in parkinson's disease

Conditions: Parkinson's Disease; Depression

Summary: the purpose of this pilot program is to develop and evaluate a new treatment program for depression in parkinson's disease (pd). the treatment uses cognitive behavior therapy(cbt)to teach patients how to become more aware of their thoughts and feelings and to change thinking patterns and behaviors that may be related to depressive symptoms. this is the first time that this treatment has been used in a group setting for depression in pd. target population is patients in the movement disorders clinic at oregon health \& science university who have parkinson's disease and mild to moderate depression.


Eligibility criteria:
inclusion criteria: * parkinson's disease, mild to moderate depression, seen at oregon health \& science university exclusion criteria: * suicidal * cognitive impairment with moca \<26

Keywords: parkinson's disease depression parkinson's disease with mild to moderate depression.
vaccination of children following allogeneic stem cell transplantation

Conditions: Allogeneic Haematopoietic Stem Cell Transplantation

Summary: the purpose of this study is to determine the immunogenicity and tolerability of the dtap-ipv-hbv/hib combination vaccine infanrix hexa and the heptavalent pneumococcal conjugate vaccine prevenar in pediatric recipients of allogeneic haematopoietic stem cell transplantation.


Eligibility criteria:
inclusion criteria: * pediatric recipient of allogeneic haematopoietic stem cell transplantation * complete remission of underlying malignant disease (if applicable) * stable haematopoietic engraftment * lansky-/karnofsky-score \>= 60% exclusion criteria: * primary immunodeficiency * hepatitis b or c, hiv infection * application of radio-/ chemotherapy following stem cell transplantation * extended chronic graft-versus-host disease (karnofsky-scale \< 60%) * coagulopathy * known allergy/hypersensitivity towards ingredients of study vaccines * seizure disorder, progressive neurologic disease

Keywords: allogeneic haematopoietic stem cell transplantation bone marrow transplantation children vaccination invasive pneumococcal disease tetanus diphtheria poliomyelitis pertussis hepatitis b haemophilus influenzae type b infection
the effect of different drugs and infusion ways on degree of postoperative comfort

Conditions: Analgesia, Patient-Controlled

Summary: to explore the effect of different drugs and infusion ways on degree of postoperative comfort.patients undergoing spinal neoplasm surgery receive different patient controlled analgesia(pca) drugs postoperatively,one group is sufentanil,the other is hydromorphone. then each drug group will be divided into two subgroups according to the infusion way,intravenously,subcutaneously. during the patient controlled analgesia period, patients' degree of comfort,pain score,sleep quality, the degree of side reaction will be recorded.


Eligibility criteria:
inclusion criteria: * american society of anesthesiologists (asa) physical status i or ii . exclusion criteria: * history of severe heart, hepatic or renal disease, * history of chronic pain condition or opioid use, * body mass index (bmi) ≤18 or ≥30 kg/m2, * alcohol or drug abuse, * relevant drug allergy, * inability to properly describe postoperative pain, * inability to use pca pump.
attentional impairment in people with epilepsy

Conditions: Epilepsy

Summary: epilepsy is one of the most common chronic neurological conditions.it leads to cognitive impairment in 20-50% of patients with a structural form. in comparison with seizures, these cognitive disorders are a major additional factor in occupational, social and family disability. they are particularly frequent (50%) in temporal epilepsies and preferably concern memory and language skills. the cognitive consequences of epilepsy are therefore well described in the following areas: episodic memory, language, executive functions. concerning attentional abilities, a recent review has highlighted the lack of work in this specific field in order to properly measure the prevalence and nature of attentional disorders in epileptic patients. indeed, attentional abilities are often mentioned in studies, but attention is a complex domain defined by four modalities: alertness, selective attention, divided attention and sustained attention. no study systematically assesses all of these modalities. the objective of this study is to evaluate the prevalence and nature of attentional disorders in epileptic patients compared to control subjects.


Eligibility criteria:
patients: inclusion criteria: * patient with epilepsy, according to fisher et al. (2005). * patient with written informed consent * affiliation to a social security regime is compulsory * individuals who have received full information about the organization of the research and have not objected to their participation and the use of their data. * patient 18 years of age and older normal controls: individuals who have received full information about the organization of the research and have not objected to their participation and the use of their data. * people 18 years of age and older * people with no neurological and/or psychiatric history exclusion criteria: for patients: with another progressive neurological condition for all people of full age who are subject to a legal protection measure or who are unable to express their consent people deprived of their liberty by a judicial or administrative decision people who regularly use psychoactive substances (cannabis, alcohol...)